Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of Lower Dose Post-Transplantation Cyclophosphamide for GVHD Prophylaxis
NCT05436418Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by National Cancer Institute. Started Nov 2022; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05436418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436418.